Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.

ABSTRACT:

Introduction

Adjuvant endocrine therapy induces bone loss and increases fracture risk in women with hormone-receptor positive, early-stage breast cancer (EBC). We aimed to update a previous position statement on the management of aromatase inhibitors (AIs) induced bone loss and now included premenopausal women.

Methods

We conducted a systematic literature search of the medical databases from January 2017 to May 2020 and assessed 144 new studies.

Results

Extended use of AIs beyond 5 years leads to persistent bone loss in breast cancer extended adjuvant trials and meta-analyses. In addition to bone mineral density (BMD), vertebral fracture assessment (VFA) and trabecular bone score (TBS) were shown to independently predict fracture risk in real life prospective s

SUBMITTER: Waqas K 

PROVIDER: S-EPMC8080519 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature